CJC-1295 dose calculator

Protocols developed for the no-DAC version (Mod GRF 1-29) are defined by frequent administration due to its rapid clearance. Dosing schedules often involve one to three administrations per day to create distinct pulses of GH release, with a common example dose being 100 mcg per instance, leading to a schedule of 7 or more administrations per week. This variant is almost always paired with a Ghrelin Receptor Agonist (a GHRP like ipamorelin) in the same syringe to amplify the pituitary's response through a secondary receptor pathway.

Conversely, protocols for CJC-1295 with DAC are structured around its long half-life, requiring much less frequent administration. A typical research schedule might involve a single administration once or twice per week, with doses that are correspondingly larger to maintain elevated GH and IGF-1 levels over the interval. The choice between these two protocols is absolute; applying a daily dosing schedule intended for the no-DAC version to the long-acting DAC version would be a significant protocol error, and vice versa.

Divergent study designs directly reflect the profound pharmacokinetic differences between the two CJC-1295 variants. Research protocols involving the no-DAC version, sometimes referred to as Mod GRF 1-29, typically schedule administrations on a daily or even multi-daily basis to account for its very short half-life and maintain stable levels for observation. As a numeric example for personal tracking, a 2 mg vial reconstituted with 2 mL would yield a concentration of 1,000 mcg/mL; a 100 mcg illustrative dose is 0.1 mL or 10 units on a U-100 syringe, logged on a daily cadence (no-DAC variant). In stark contrast, studies observing the DAC variant plan for a much lower administration frequency, often weekly, to align with its long-lasting presence in circulation.

Both forms of CJC-1295 are analogs of GHRH and function by binding to and stimulating the Growth Hormone Releasing Hormone receptor (GHRHr) in the anterior pituitary gland. Stimulation of this receptor initiates the downstream cascade that results in the synthesis and release of growth hormone. The core peptide sequence responsible for this action is the first 29 amino acids of GHRH, which is what the 'no-DAC' variant (Mod GRF 1-29) comprises, with four specific amino acid substitutions to inhibit degradation.

The key divergence occurs with the addition of the Drug Affinity Complex. The DAC version includes a lysine residue linked to maleimidopropionic acid, which forms a covalent bond with the protein serum albumin after administration. This binding protects the peptide from enzymatic degradation by dipeptidyl peptidase-4 (DPP-IV) and dramatically reduces its clearance rate by the kidneys. This novel mechanism effectively turns circulating albumin into a temporary carrier for the peptide, extending its biological half-life from mere minutes to a span of 6-8 days.

The mechanism responsible for the extended duration of CJC-1295 with DAC involves a precise and stable chemical modification. The DAC component is a specialized maleimidopropyl group that is chemically reactive towards thiol groups, such as those found on cysteine residues within proteins. In the bloodstream, this group selectively forms a strong, covalent bond with a specific cysteine residue (Cys34) of circulating albumin. Once this bond is formed, the large albumin protein effectively acts as a carrier vehicle, sterically shielding the much smaller GHRH analog from rapid enzymatic degradation and renal clearance. This process of 'albumin-hitching' is what transforms the peptide's kinetic profile, increasing its half-life from minutes to several days, a central concept researchers study when they observe its long-term activity.